Cytology samples and molecular biomarker testing in lung cancer—advantages and challenges-Reference-Cited by-同舟云学术

Cytology samples and molecular biomarker testing in lung cancer—advantages and challenges

Published:2021-01 Issue:1 Volume:478 Page:45-57
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Canberk Sule^ORCID,Engels Marianne

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00428-020-02995-2.pdf

Reference55 articles.

1. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed 14 March 2019

2. Lindeman NI, Cagle PT, Beasley MB et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 137:828–860

3. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 142(3):321–346. https://doi.org/10.5858/arpa.2017-0388-CP

4. Van Hoef MEHM (2018) Additional recommendations for ALK gene-rearranged non-small-cell lung cancer to the recently updated American Society of Clinical Oncology guideline for stage IV non-small-cell lung cancer. J Clin Oncol 36(4):427. https://doi.org/10.1200/JCO.2017.75.8367

5. Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, O'Byrne K, Stahel R, Peters S, Felip E, Stahel R, Felip E, Peters S, Kerr K, Besse B, Vansteenkiste J, Eberhardt W, Edelman M, Mok T, O'Byrne K, Novello S, Bubendorf L, Marchetti A, Baas P, Reck M, Syrigos K, Paz-Ares L, Smit EF, Meldgaard P, Adjei A, Nicolson M, Crinò L, van Schil P, Senan S, Faivre-Finn C, Rocco G, Veronesi G, Douillard JY, Lim E, Dooms C, Weder W, de Ruysscher D, le Pechoux C, de Leyn P, Westeel V (2014) Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 25(9):1681–1690. https://doi.org/10.1093/annonc/mdu145

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The rationale for the development and publication of the World Health Organization reporting systems for cytopathology and a brief overview of the first editions of the lung and pancreaticobiliary systems;Cancer Cytopathology;2023-09-13

2. A brief review of the WHO reporting system for lung cytopathology;Journal of the American Society of Cytopathology;2023-07

3. A Critical Issue in Lung Cancer Cytology and Small Biopsies: DNA and RNA Extraction from Archival Stained Slides for Biomarker Detection through Real Time PCR and NGS—The Experience in Pathological Anatomy Unit;Diagnostics;2023-05-05

4. Nueva actualización de las recomendaciones para la determinación de biomarcadores predictivos en el carcinoma de pulmón no célula pequeña: Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica;Revista Española de Patología;2023-04

5. Recommendations for optimizing the use of cytology in the diagnosis and management of patients with lung cancer;Revista Española de Patología;2023-01